Menopausal Hormone Labels Should Rely on Evidence, Not Opinion

This Viewpoint from the DSMB of the Women’s Health Initiative studies discusses weighing the evidence of benefits and risks of various estrogen products following the FDA’s decision to remove most box warnings from hormone replacement therapy products.

Corresponding Author: Janet Wittes, PhD, Wittes LLC, 2324 California St NW, Washington, DC 20008 (janet@wittesllc.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.